| Followers | 832 |
| Posts | 119978 |
| Boards Moderated | 17 |
| Alias Born | 09/05/2002 |
Wednesday, October 07, 2009 2:02:39 AM
Two more reasons to question DB’s report on MNTA:
1. Robyn Karnauskas (the lead Deutsche Bank analyst assigned to MNTA) says MNTA is worth $18/sh without any contribution from Lovenox while also arguing that the share price will fall to $6 or less if the FDA approves more than one generic Lovenox (which would, of course, provide MNTA some economic value attributable to Lovenox). This is so bizarre that I need to state it again: Karnauskas says MNTA would be worth $18/sh if the Lovenox program did not even exist, but she expects the share price to fall to $6 if the FDA approves multiple generics. A real head-scratcher!
2. Karnauskas stated that MNTA uses enzymatic cleavage to make generic Lovenox from bulk heparin, but they do not—they use only chemical (i.e. small-molecule) cleavage. This seemingly small distinction is sufficiently relevant that a scientist from MNTA corrected Karnauskas during a recent CC on exactly this point. Inasmuch as Karnauskas is a professional analyst who has made a big deal to the investment community about her “DD” on MNTA, I would expect her to know a detail such as this; I knew this two years ago and I’m just an investor: #msg-24438508
FWIW
1. Robyn Karnauskas (the lead Deutsche Bank analyst assigned to MNTA) says MNTA is worth $18/sh without any contribution from Lovenox while also arguing that the share price will fall to $6 or less if the FDA approves more than one generic Lovenox (which would, of course, provide MNTA some economic value attributable to Lovenox). This is so bizarre that I need to state it again: Karnauskas says MNTA would be worth $18/sh if the Lovenox program did not even exist, but she expects the share price to fall to $6 if the FDA approves multiple generics. A real head-scratcher!
2. Karnauskas stated that MNTA uses enzymatic cleavage to make generic Lovenox from bulk heparin, but they do not—they use only chemical (i.e. small-molecule) cleavage. This seemingly small distinction is sufficiently relevant that a scientist from MNTA corrected Karnauskas during a recent CC on exactly this point. Inasmuch as Karnauskas is a professional analyst who has made a big deal to the investment community about her “DD” on MNTA, I would expect her to know a detail such as this; I knew this two years ago and I’m just an investor: #msg-24438508
FWIW
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
